Ann: Epichem enters voluntary liquidation, page-119

Great post ID2T,

I am also VERY interested to hear what other shareholders prefer, but I guess the question should be, does the board have the energy to pursue the potential of MPL on other indications.

They have been saying we will licence along the way to exploring other indications, then expect it to be taken over by one entity.

Is anyone else here going to be content to see MPL sold after being trialled on MND, a $3.6 Billion addressable market, when there is a chance to address a market where a 1% reduction in mortality, in the US alone, has a value of $500 Billion?

”Cure for Cancer worth $50 Trillion”

https://www.sciencedaily.com/releases/2006/04/060426174214.htm

Lets not talk too much about MPL’s value as an all-encompassing antiviral, but I think I saw a video where RM said COVID19 was approximately $10 Billion a year.

MND could just be the “tip of the iceberg”, and I am not convinced about the good Dr RA’s energy to get through this…

Can anyone get any information, about anything, from the company at this stage?

Regards,

Havelots